TIGIT Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

Key Highlights:

• T cell Immunoreceptor with Immunoglobulin and ITIM Domain (TIGIT) inhibitor is linked with PD-1 expression, and it can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have demonstrated the potential benefits of co-inhibition of TIGIT and PD-1/PD-L1 in enhancing anti-tumor immunity and improving treatment outcomes in several cancer types.
• The epidemiology pool targeting TIGIT inhibitors includes various indications like Renal Cell Carcinoma (RCC), Non Small Cell Lung Cancer (NSCLC), colorectal cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), melanoma, and other indications.
• Currently, there is no approved TIGIT inhibitor. The emerging landscape has been pruning in the past years with trial terminations like belrestotug, etigilimab, AGEN1777, and other therapies.
• The current few emerging therapies include domvanalimab (Arcus Biosciences and Gilead Sciences) and rilvegostomig (AstraZeneca, Compugen, and Daiichi Sankyo), and other therapies.
• Given that TIGIT can limit multiple aspects of tumor immunity, co-expressed, and synergistic with PD-1 in a variety of malignant tumors, it has become another Immune Checkpoint Pathway (ICP) that has garnered significant attention after the PD-1/PD-L1 era.
• Trial inconsistencies have triggered a sharp pullback in investment within the TIGIT landscape. Nonetheless, the anticipated approvals of domvanalimab and rilvegostomig may serve as inflection points, restoring industry momentum and catalyzing the development of next-generation therapies.

DelveInsight's "TIGIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report delivers an in-depth understanding of TIGIT Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The TIGIT Inhibitors market report provides insights around existing treatment practices in patients with TIGIT Inhibitors, approved (if any) and emerging TIGIT Inhibitors, market share of individual therapies, patient pool eligible for treatment with TIGIT Inhibitors, along with current and forecasted 7MM TIGIT Inhibitors market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new TIGIT Inhibitors in different geographies, along with insights on TIGIT Inhibitors pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

TIGIT Inhibitors Overview

T cell Immunoreceptor with Immunoglobulin and ITIM Domain (TIGIT) inhibitor is linked with PD-1 expression, and it can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have demonstrated the potential benefits of co-inhibition of TIGIT and PD-1/PD-L1 in enhancing anti-tumor immunity and improving treatment outcomes in several cancer types.

Target Patient Pool Analysis

• Among lung cancer cases, NSCLC accounts for approximately 85% of all diagnoses. This distribution highlights that NSCLC is the more prevalent form of lung cancer.
• According to European Association of Urology (n.a.), RCC ranks 14th on the list of cancers, representing around 2% of all cancers, with the highest incidence occurring in Western countries. In 2022, there were an estimated 434,840 new cases of RCC globally with 155,953 deaths worldwide.
• As per World Health Organization (2023), in 2020, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide.
• Klairmont et al. (2026) reported that the epidemiology of PTCL accounts for 30% cases in the Western countries.

TIGIT Inhibitors Drug Chapters

The drug chapter segment of the TIGIT Inhibitors report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the TIGIT Inhibitors clinical trial details, pharmacological action, agreements and collaborations related to TIGIT Inhibitors, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

TIGIT Inhibitors Emerging Drugs

Domvanalimab: Arcus Biosciences and Gilead Sciences

Domvanalimab is a humanized IgG1 monoclonal antibody targeting the immune checkpoint TIGIT. By blocking TIGIT interaction with CD112 and CD155, it enhances CD226-mediated signaling on NK cells and CD8+ T cells, thereby strengthening anti-tumor immune responses. Domvanalimab is currently under evaluation in NSCLC and upper gastrointestinal cancers.

In October 2025, Arcus Biosciences reported the first OS results from Arm A1 of the Phase II (EDGE-Gastric) study in patients with advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma. The global, multi-arm study evaluates domvanalimab plus zimberelimab and chemotherapy, in partnership with Gilead Sciences, with results to be presented at ESMO 2025.

Rilvegostomig: AstraZeneca, Compugen, and Daiichi Sankyo

Rilvegostomig is a bispecific antibody targeting PD-1 and TIGIT. By simultaneously inhibiting PD-1-PD-L1/PD-L2 and TIGIT-CD112/CD155 interactions, it restores T-cell function and enhances CD226-mediated signaling on NK cells and CD8+ T cells, thereby promoting anti-tumor immune responses. Rilvegostomig is under evaluation in NSCLC, HNSCC, biliary tract cancer, and other solid tumors.

In December 2025, Compugen and AstraZeneca amended their 2018 exclusive license agreement, allowing Compugen to monetize a portion of its future rilvegostomig royalties to strengthen its balance sheet and support advancement of its immuno-oncology pipeline.

AstraZeneca is also leveraging its partnership with Daiichi Sankyo to test combinations of the TIGIT with the Antibody-drug Conjugate (ADC) DATROWAY for specific subtypes of NSCLC.

Recent Developments in the TIGIT Inhibitors Market

• In December 2025, Compugen and AstraZeneca amended their 2018 exclusive license agreement, allowing Compugen to monetize a portion of its future royalties from rilvegostomig to strengthen its balance sheet and support the advancement of its immuno-oncology pipeline.
• In October 2025, Arcus Biosciences reported the first OS results from Arm A1 of the Phase II (EDGE-Gastric) study in patients with advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma. The global, multi-arm study evaluates domvanalimab plus zimberelimab in combination with chemotherapy, in partnership with Gilead Sciences, with results to be presented at ESMO 2025.
• In September 2025, Genentech presented Phase III results at the European Society for Medical Oncology Congress 2025 (ESMO 2025) for tiragolumab in combination with atezolizumab and bevacizumab as first-line treatment in patients with untreated locally advanced or metastatic Hepatocellular Carcinoma (HCC).

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on TIGIT Inhibitors as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of TIGIT Inhibitors, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

TIGIT Inhibitors Market Outlook

This section will include details on changing TIGIT Inhibitors market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

TIGIT Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential TIGIT Inhibitors already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

TIGIT Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

TIGIT Inhibitors Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for TIGIT Inhibitors.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on TIGIT Inhibitors' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on TIGIT Inhibitors addressable patient pool
• A detailed review of the TIGIT Inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM TIGIT Inhibitors market.
• Market Size of Inhibitors by therapies and indication will be provided

TIGIT Inhibitors Report Key Strengths

• 11 Years TIGIT Inhibitors Market Forecast
• The 7MM Coverage
• TIGIT Inhibitors Competitive Landscape of current and emerging therapies
• TIGIT Inhibitors Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• TIGIT Inhibitors Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the TIGIT Inhibitors total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for TIGIT Inhibitors market growth?
• Which TIGIT Inhibitor is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of TIGIT Inhibitors?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the TIGIT Inhibitors Market.
• Understand the existing TIGIT Inhibitors market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.